Tandemact (pioglitazone;glimepiride)
- Region
- 🇪🇺 EU
- Active substance
- pioglitazone;glimepiride
- Company
- CHEPLAPHARM Arzneimittel GmbH
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus, Type 2
- EU approval
- Mon 08 Jan 2007
- Application
- EMEA/H/C/000680
- ATC
- A10BD06
- Official record
- www.ema.europa.eu
Indication
Tandemact is indicated for the treatment of patients with type-2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of pioglitazone and glimepiride.
Regulatory milestones
No milestones recorded in the last year.
Follow Tandemact
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.